Lexeo Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights

Lexeo announces $95.0M equity financing, which in addition to 2023 year-end cash and cash equivalents of $121.5M, extends runway to fund operations into 2027 Reports frataxin protein expression data...

Related Keywords

New York ,United States ,Carolyn Hawley ,Laurence Watts ,R Nolan Townsend ,Lexeo Therapeutics Inc ,Exchange Commission ,Nasdaq ,Program Updates ,Globenewswire Inc ,Nolan Townsend ,Chief Executive Officer ,Chromatography Mass Spectrometry ,Assay Protein Expression ,Fast Track ,Orphan Drug ,Disease Programs ,Equity Financing ,Initial Public Offering ,Full Year Financial ,York City Based ,Quarterly Report ,Safe Harbor ,Private Securities Litigation Reform Act ,Consolidated Statements ,